Newsroom

September 24, 2020

A randomized, blinded, controlled USA field study to assess the use of fluralaner topical solution in controlling feline flea infestations

Abstract Background: Fleas are a common ectoparasite of domestic cats and there is a need for novel treatments that improve feline flea control. Methods: This investigator-blinded, multi-center randomized, positive-controlled study evaluated the flea control in cats provided by a single owner-applied treatment with a fluralaner topical formulation compared with a positive control. Households with up […]

August 24, 2020

Three-Year Duration of Immunity in Cats Following Vaccination against Feline Rhinotracheitis Virus, Feline Calicivirus, and Feline Panleukopenia Virus

Clinical Relevance Forty-two seronegative cats received an initial vaccination at 8 weeks of age and a booster vaccination at 12 weeks. All cats were kept in strict isolation for 3 years after the second vaccination and then were challenged with feline calicivirus (FCV) or sequentially challenged with feline rhinotracheitis virus (FRV) followed by feline panleukopenia […]

August 24, 2020

Efﬁcacy of an Inactivated FeLV Vaccine Compared to a Recombinant FeLV Vaccine in Minimum Age Cats Following Virulent FeLV Challenge

Abstract The aim of the study was to determine the efﬁcacy of an inactivated feline leukemia virus (FeLV) vac-cine (Versifel® FeLV, Zoetis.) compared to a recombinant FeLV vaccine (Purevax® FeLV, Merial Animal Health) in young cats, exposed under laboratory conditions to a highly virulent challenge model. The study was designed to be consistent with the general immunogenicity […]

August 24, 2020

Comparative Efficacy of Feline Leukemia Virus Inactivated Whole Virus Vaccine and Canarypox Virus-Vectored Vaccine by Modern Molecular Assays and Conventional Parameters

Purpose The purpose of this study was to compare the efficacy of two commercially available feline leukemia vaccines, Nobivac® Feline 2-FeLV (inactivated whole virus vaccine) and PureVax® Recombinant FeLV (live canarypox virus-vectored vaccine) following challenge with virulent feline leukemia virus. Read More about this study here

August 24, 2020

Feline Leukemia Virus Immunity Induced by Whole Inactivated Virus Vaccination

Abstract A fraction of cats exposed to feline leukemia virus (FeLV) effectively contain virus and resist persistent antigenemia/viremia. Using real-time PCR (qPCR) to quantitate circulating viral DNA levels, previously we detected persistent FeLV DNA in blood cells of non-antigenemic cats considered to have resisted FeLV challenge. In addition, previously we used RNA qPCR to quantitate […]

August 24, 2020

Feline Leukaemia Virus: a Review of Immunity and Vaccination

The availability of feline leukaemia virus {FeLV) vaccines has added a new and important dimension to the control of this infectious agent. FeLV vaccination is a controversial issue, however, partly because of differences in the formulation between the current products, partly because of conflicting claims by vaccine manufacturers and partly because experimental trials have shown […]

August 24, 2020

lmmunogenicity and Efficacy of a Commercial Feline Leukemia Virus Vaccine

Twenty young adult specific pathogen-free cats were randomly divided into two groups of 10 animals each. One group was vaccinated with two doses of feline leukemia virus vaccine according to the manufacturer’s recommendations. All 20 cats were challenge exposed oronasally (4 times over a I-week period), beginning 3 weeks after immunization, with a virulent subgroup […]

August 24, 2020

Comparitive Efficacy of Feline Leukemia Virus Inactivated Whole Virus Vaccine and Canarypox Virus-Vectored Vaccine by Molecular Assays and Conventional Parameters

August 20, 2020

Read

August 17, 2020

Client Discharge Form

Create a customized, printable form for clients about their new diagnosis.